Bioceltix Cash Flow Statement

Financials in millions PLN. Fiscal year is January - December.

Millions PLN. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-14.49	-14.9	-13.69	-8.92	-4.4
Depreciation & Amortization	0.65	0.57	0.43	0.45	0.38
Loss (Gain) From Sale of Assets	-0.05	-0.05	-	-0.05	-0.07
Other Operating Activities	0.21	0.17	0.03	0.03	0.02
Change in Accounts Receivable	-3.09	-3.09	-1.51	0.22	-0.25
Change in Inventory	0.02	-0.01	-0.01	-	0.01
Change in Other Net Operating Assets	0.79	-0.27	-0.01	0.41	0.29
Operating Cash Flow	-15.96	-17.57	-14.75	-7.87	-4.02
Capital Expenditures	-0.45	-0.24	-0.46	-0.35	-0.01
Sale of Property, Plant & Equipment	0.16	0.16	-	-	0.14
Investing Cash Flow	-0.29	-0.08	-0.46	-0.35	0.13
Long-Term Debt Repaid	-	-0.71	-0.12	-0.21	-0.42
Net Debt Issued (Repaid)	-0.82	-0.71	-0.12	-0.21	-0.42
Issuance of Common Stock	42.85	42.85	20.67	6.53	7.17
Other Financing Activities	-0.21	-0.17	-0.15	-0.03	-0.02
Financing Cash Flow	41.82	41.97	20.4	6.29	6.74
Net Cash Flow	25.57	24.32	5.19	-1.93	2.85
Free Cash Flow	-16.41	-17.81	-15.21	-8.23	-4.02
Free Cash Flow Per Share	-3.46	-3.93	-3.88	-2.47	-1.27
Cash Interest Paid	0.17	0.17	0.03	0.03	0.02
Levered Free Cash Flow	-10.44	-12.61	-8.89	-6.36	-
Unlevered Free Cash Flow	-10.31	-12.5	-8.87	-6.34	-
Change in Net Working Capital	1.37	3.41	0.09	0.84	-

Updated Nov 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.